Semmelweis University

SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors

Retrieved on: 
Thursday, March 14, 2024
Research, Certification, Growth, Novartis, Patient, University, MD, MBA, Semmelweis University, Pleasure, Research and development, Corvinus University of Budapest, Marketing, Nursing

“It is with pleasure that I welcome Zsuzsanna, the Global Head, Medical Affairs, Oncology, Novartis, to our Board of Directors,” said Shadi Farhangrazi, Chief Executive Officer of SMDG and chairman of the board.

Key Points: 
  • “It is with pleasure that I welcome Zsuzsanna, the Global Head, Medical Affairs, Oncology, Novartis, to our Board of Directors,” said Shadi Farhangrazi, Chief Executive Officer of SMDG and chairman of the board.
  • “Not only is Zsuzsanna an exceptional leader, she is also a passionate physician and scientist.
  • Zsuzsanna and our team share a common vision of bringing transformative therapies to patients.”
    Dr. Devecseri added, “I am thrilled to join the team and the board of SMDG.
  • Dr. Devecseri has had the opportunity to build and lead high-performing, engaged teams, and has gained a deep understanding of healthcare systems globally.

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

Retrieved on: 
Wednesday, January 17, 2024
Mortality, Death, Patient, Incidence, ICU, Cytokine adsorbing column, Vasoplegic syndrome, Semmelweis University, Professional corporation, DRS, European Society of Cardiology, RCT, Heart, Standard of care, Pelvic floor dysfunction, Cytosorbents Corporation, Circulatory system, Risk, Organ dysfunction, VS, Multiple organ dysfunction syndrome, Observational study, Shock, Randomized controlled trial, ESC, Dentistry

In particular, vasoplegic syndrome (VS), a form of circulatory failure or shock, is routinely seen in these patients and can cause worsened organ failure.

Key Points: 
  • In particular, vasoplegic syndrome (VS), a form of circulatory failure or shock, is routinely seen in these patients and can cause worsened organ failure.
  • In a prior observational study , CytoSorb was associated with the reduced severity of vasoplegia in heart transplant patients, in addition to other clinical benefits.
  • In this prospective, single-center, open-label RCT, 60 heart transplant recipients were randomly assigned to either receive intraoperative CytoSorb hemoadsorption or standard of care.
  • Now, Nemeth, Soltesz, and colleagues have confirmed many of these observations in this rigorous and well-designed groundbreaking randomized controlled trial in orthotopic heart transplant patients.

Los Angeles Cancer Network Opens New Location in Santa Clarita

Retrieved on: 
Tuesday, September 19, 2023
Olive, Cedars-Sinai Medical Center, University, Internal medicine, Patient, Central European, Cancer, Olive View–UCLA Medical Center, Physician, Semmelweis University, Keck School of Medicine of USC, Harbor–UCLA Medical Center, University of Mississippi Medical Center, Nursing

SANTA CLARITA, Calif., Sept. 19, 2023 /PRNewswire/ -- Los Angeles Cancer Network (LACN) has been a trusted provider of cancer and blood disorder care in the Los Angeles area for over 30 years.

Key Points: 
  • SANTA CLARITA, Calif., Sept. 19, 2023 /PRNewswire/ -- Los Angeles Cancer Network (LACN) has been a trusted provider of cancer and blood disorder care in the Los Angeles area for over 30 years.
  • Last week, on September 12, 2023, the ribbon was cut at their newest location at 25425 Orchard Village Rd.
  • Suite 150, Santa Clarita, CA 91355, where they will be providing world-class care to patients in the Santa Clarita and surrounding communities.
  • Board-certified hematologist/oncologists Dr. Sheila Vasan and Dr. Krisztina Larson will practice at the newest location in Santa Clarita.

VIALASE ANNOUNCES PUBLICATION OF 24-MONTH SAFETY DATA FROM FIRST IN-HUMAN STUDY OF FEMTOSECOND LASER IMAGE-GUIDED HIGH-PRECISION TRABECULOTOMY (FLigHT)

Retrieved on: 
Tuesday, April 18, 2023
Glaucoma, Science, IOP, Trabecular meshwork, Eye, American Academy, American Academy of Ophthalmology, Doctor of Philosophy, Intraocular pressure, Patient, Semmelweis University, Flight, Collateral damage, Health, Safety, Medical imaging, Pharmaceutical industry, Ophthalmology, MD

ALISA VIEJO, Calif., April 18, 2023 /PRNewswire/ -- ViaLase, Inc., a clinical stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm with the development of a truly noninvasive image-guided femtosecond laser treatment to enhance glaucoma patient care, today announced the online publication of 24-month safety data from the first-in-human study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) performed with the ViaLase technology in Ophthalmology® Science, a journal of the American Academy of Ophthalmology.

Key Points: 
  • ViaLase's FLigHT treatment leverages the precision and accuracy of both a femtosecond laser and advanced imaging technology in a noninvasive procedure.
  • At 24 months post-treatment, the authors reported no device-related serious adverse events and observed well-defined channels with no evidence of closure, indicating medium-term durability.
  • The data demonstrated a mean IOP reduction of 34.6% from baseline of 22.3 ± 5.5 to 14.5 ± 2.6 mmHg at 24 months.
  • The IOP reductions observed in this study are encouraging and will be further evaluated as part of the multicenter clinical trial currently underway.

Radionetics Oncology Appoints Istvan Molnar, M.D. as Chief Medical Officer

Retrieved on: 
Wednesday, February 22, 2023
Medical Devices, Hospitals, Clinical Trials, Cardiology, Biotechnology, Radiology, Health, Pharmaceutical, General Health, Knowledge, Irinotecan, Acute leukemia, Cancer, Prostate cancer, Merrimack Pharmaceuticals, Sorafenib, Wake Forest University School of Law, Assistant, Radiopharmaceutical, Myelodysplastic syndrome, Semmelweis University, Drug, Bayer, Wake Forest University, Therapy, Haematopoietic system, Wake Forest School of Medicine, Pharmaceutical industry, Medicine

Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, is pleased to announce the appointment of Istvan Molnar, M.D.

Key Points: 
  • Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, is pleased to announce the appointment of Istvan Molnar, M.D.
  • as Chief Medical Officer.
  • Dr. Molnar is an industry veteran bringing 15 years of experience in oncology clinical development, including significant expertise in radiopharmaceutical drug development.
  • Dr. Molnar has a broad background in oncology and radiopharmaceutical drug development spanning early- to late-stage projects with extensive global experience in clinical development, regulatory, medical affairs, and drug safety.

Amolyt Pharma to Host Hybrid Key Opinion Leader Event on its Potential Hypoparathyroidism Treatment, AZP-3601, on Monday, September 12th at 1:30pm CT/2:30pm ET in Austin, Texas

Retrieved on: 
Wednesday, September 7, 2022
Acromegaly, Doctor of Science, Osteoporosis, Study, Genetics, Doctor of Philosophy, Semmelweis University, Disease, Medical school, Internal medicine, Endocrinology, LinkedIn, Department, Latvian Biomedical Research and Study centre, Department of Medicine – University of Pamplona, Hypoparathyroidism, Student, Thyroid, MD, GLOBE, Pharmacology, Twitter, Osteology, Association, PTH, Hungarian Academy of Sciences, Patient, Fine chemical, Pharmaceutical industry, Medicine, Research

The event will also be webcast for those who are unable to attend in person.

Key Points: 
  • The event will also be webcast for those who are unable to attend in person.
  • Professor Istvn Takcs obtained his MD in 1989 from Semmelweis University, Faculty of Medicine, in Budapest, Hungary.
  • He was board certified in internal medicine in 1994, in endocrinology in 1997 and in clinical pharmacology in 2001.
  • To learn more, visit https://amolytpharma.com/ or follow us on Twitter at @AmolytPharma or on LinkedIn .

Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head

Retrieved on: 
Tuesday, August 23, 2022
Alexion, Schizophrenia, MDR, Semmelweis University, COVID-19, The Company, University, XDR, Ophthalmology, Business administration, Research, Central nervous system, Therapy, Rice University, Master of Business Administration, Time, Lists of diseases, Infection, MIT, SVP, CMC, School, Multimedia, Hepatitis B, Alexander, HIV, Health, Company, FDA, Doctor of Philosophy, Biotechnology, Stanford University, Chemical engineering, Merck, University of Novi Sad Faculty of Technical Sciences, Sanofi, Growth, Master of Science, CNS, Anxiety, Temple University School of Medicine, Otsuka Pharmaceutical, Patient, Pharmaceutical industry, Medicine, Medicine, Brexpiprazole, Operation

DURHAM, N.C. and BEIJING, Aug. 22, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced the appointments of Eleanor (Ellee) de Groot, Ph.D., as Chief Technology Officer and Aleksandar Skuban, M.D., as Central Nervous System (CNS) Diseases Therapy Area Head.

Key Points: 
  • DURHAM, N.C. and BEIJING, Aug. 22, 2022 /PRNewswire/ -- Brii Biosciences Limited("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced the appointments of Eleanor (Ellee) de Groot, Ph.D., as Chief Technology Officer and Aleksandar Skuban, M.D., as Central Nervous System (CNS) Diseases Therapy Area Head.
  • "Ellee and Aleksandar are both seasoned biotech leaders with impressive credentials and an entrepreneurial history of leading medicine development and manufacturing initiatives within their functional areas.
  • Prior to that, he served as an Executive Medical Director leading clinical development within Alexion's emerging ophthalmology therapeutic area.
  • "I am inspired by the meaningful patient-centric approach that Brii Biohas cultivated in the earliest stages of clinical planning.

ORION BIOTECHNOLOGY ADDS GPCR EXPERT TO ITS SCIENTIFIC ADVISORY BOARD

Retrieved on: 
Tuesday, July 5, 2022
Pathology, LinkedIn, Chemokine, GLOBE, Orion, Queen Mary University of London, Growth, Cancer, Semmelweis University, Gq alpha subunit, SAB, Pharmacology, G protein-coupled receptor, Inflammation, Experimental pathology, Therapy, National Cancer Institute, Novartis Institute for Tropical Diseases, National, Drug discovery, Fine chemical, GPCR

Ottawa, Canada, July 05, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a drug discovery and development company targeting previously-undruggable G Protein-Coupled Receptors (GPCRs), today announced that Dr. Antal Rot, a world-renowned expert in the role of chemokines in inflammation, has joined Orions scientific advisory board (SAB).

Key Points: 
  • Ottawa, Canada, July 05, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a drug discovery and development company targeting previously-undruggable G Protein-Coupled Receptors (GPCRs), today announced that Dr. Antal Rot, a world-renowned expert in the role of chemokines in inflammation, has joined Orions scientific advisory board (SAB).
  • at the Semmelweis University in Budapest, Hungary before completing his post-doctoral research training at the National Cancer Institute (Frederick, USA) in the lab of Edward Leonard.
  • Orion Biotechnology Canada Ltd. is unlocking the therapeutic potential of previously-undruggable G Protein-Coupled Receptors (GPCRs).
  • With its team of world-renowned experts in GPCR pharmacology and peptide/protein engineering, Orion Biotechnology is well-positioned to improve patient outcomes.

LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS

Retrieved on: 
Monday, April 11, 2022
Private Securities Litigation Reform Act, Therapy, Testosterone, Adult, Research, SEC, CEO, Baxter International, Cirrhosis, Hydroxyprogesterone caproate, PDL, University, Massachusetts General Hospital, School of Medicine, University of Patras, Michele Cavion, SVP, SALT, NASH, Form 8-K, Biogen, Lists of diseases, Founder, SoftBank Group, NASDAQ, Multimedia, Business, Board, Neuroscience, CDO, Board of directors, Hypogonadism, Spiro, Biopharmaceutical, Preterm birth, DePaul University, Adamantas, NAS, FDA, Andreessen Horowitz, Company, Business development, Principal, Form 10-K, Leadership, Pfizer, Allergan, Parkinson's disease, Corporate development, Epilepsy, Semmelweis University, Management, Pharmaceutical industry, Chemistry, Development, Assertio Therapeutics

SALT LAKE CITY, April 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, announced today the appointment of Jill M. Jene, Ph.D. and Spyros Papapetropoulos, M.D., Ph.D. to its board of directors.

Key Points: 
  • "We are very pleased to welcome Jill Jene and Spyros Papapetropoulos to our board of directors.
  • Each of them brings a wealth of relevant expertise," said Mahesh V. Patel, Ph.D., Chairman and CEO of Lipocine.
  • We are confident that the insights and contributions of Jill and Spyros will strengthen the Board and we are enthusiastic about the role they can play in helping Lipocine succeed."
  • Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

SymphonyAI Announces Enterprise AI Research Partnership with Semmelweis University Heart and Vascular Center to Predict Healthcare Outcomes

Retrieved on: 
Tuesday, July 13, 2021
Ignaz Semmelweis, Semmelweis University, Medicine, Health

LOS ALTOS, Calif., July 13, 2021 /PRNewswire/ -- SymphonyAI, a leader in high-value enterprise AI solutions for key vertical sectors, announced today the expansion of a partnership with Semmelweis University Heart and Vascular Center, a leading research institution in East-Central Europe.

Key Points: 
  • LOS ALTOS, Calif., July 13, 2021 /PRNewswire/ -- SymphonyAI, a leader in high-value enterprise AI solutions for key vertical sectors, announced today the expansion of a partnership with Semmelweis University Heart and Vascular Center, a leading research institution in East-Central Europe.
  • Under the partnership, Semmelweis University researchers use SymphonyAI's EurekaAI platform to detect higher cardiovascular risk and predict patient outcomes through AI-based analysis of Semmelweis' historical patient data sets.
  • Semmelweis researchers use EurekaAI to analyze historical patient data to predict major adverse cardiac events in current patients.
  • "Semmelweis University researchers are at the forefront of using AI in the life sciences and healthcare fields," said Brennan Murphy, vice president at SymphonyAI Government Solutions, a division of SymphonyAI.